Hematologist
CION Cancer Clinics
How often MGUS turns into myeloma | CION Cancer Clinics
On average, about 1 in 100 people with MGUS develop myeloma or a related condition each year, and most never do. That average is not your number. Your own risk depends on how much M-protein you have, which type it is and your light chain ratio. This page explains each one, and what it can and cannot tell you. At CION Cancer Clinics, our haematology team plans myeloma and lymphoma care with you, discussed at a tumour board and explained in plain words.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
The short answer
How likely is MGUS to turn into myeloma?
Not very likely in any single year. On average, about 1 in 100 people with MGUS develop myeloma or a related condition each year, and most people with MGUS never do.
Why a yearly figure can feel bigger than it is
That average does not rise year on year. It stays roughly the same for as long as you have MGUS. Because MGUS is usually found later in life, many people live out their full lives without it ever changing. Other health conditions, such as heart disease or diabetes, often matter more to their long-term health than the MGUS does.
Why the average is not your number
The average mixes people at very different levels of risk. Someone with a small amount of IgG protein and normal light chains sits well below it. Someone with a larger amount of an unusual type sits above it. Your haematologist places you in a group using your own reports, and that group is far more useful to you than the average.
What "a related condition" means
Depending on the protein type, the condition being watched for may be myeloma, a slow-growing lymphoma, or amyloidosis, where the protein builds up in organs such as the kidneys or heart. Light chain MGUS is watched most closely for kidney problems. Knowing your type tells you which of these your doctor has in mind when reading each new report.
These figures describe large groups of people. They cannot predict what will happen to one person.What shapes the risk
Which results on your report raise or lower the risk?
Doctors mainly look at three things. Each is already on your protein test reports, so you can ask about each one directly.
How much M-protein there is
A smaller amount carries a lower risk. A larger amount carries a higher one. The trend across tests matters as much as one reading.
Ask your doctor
- Is my level small or large for MGUS?
- Has it changed since the first test?
Which type of protein it is
IgG is the most common and carries the lowest risk. IgA and IgM carry a somewhat higher risk. IgM is watched more for lymphoma than for myeloma.
The free light chain ratio
This compares the two kinds of light chain, kappa and lambda. A normal ratio is reassuring. An abnormal ratio adds to the risk and usually means closer follow-up.
Anything found in the marrow
If you had a bone marrow test, a higher share of plasma cells points to a higher risk. A share above the MGUS range changes the diagnosis to smouldering myeloma.
Not sure whether this applies to you?
Ask an oncologistOn the clinic letter
What do the risk group names mean?
- Low-risk MGUS
- IgG type, a small amount of protein and a normal light chain ratio. The chance of change is well below the average.
- Low-intermediate risk
- One of the three features is outside the low-risk range. Follow-up is usually a little closer.
- High-intermediate or high risk
- Two or all three features are present. The chance of change is above average, and your haematologist may add scans or a marrow test.
- Progression
- The point at which MGUS becomes myeloma or a related condition that needs a new plan.
- Evolving pattern
- A protein level that climbs steadily over several tests. It is watched more closely than a level that stays flat.
If it does change
How would a change usually be noticed?
-
A rise on a routine test
Most changes are picked up on a planned blood test before you feel anything. This is exactly why the follow-up tests are worth keeping.
-
A repeat test to confirm it
One higher result can be a laboratory difference. Your doctor usually repeats the test, ideally in the same laboratory, before acting on it.
-
A fuller check
Blood counts, calcium, kidney tests, a bone marrow test and imaging of the bones show whether the plasma cells are now affecting the body.
-
A new name and a new plan
If there is no organ damage, the result may be smouldering myeloma, which is still watched. If there is damage, it is myeloma, and treatment is discussed.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Commonly believed
What do people get wrong about the risk?
"Every year I have MGUS, the risk gets higher."
For most people the yearly chance stays about the same. Having had stable MGUS for many years is, if anything, a reassuring sign.
"Stress or worry can make MGUS progress."
There is no evidence that worry changes the protein. Worry does change how you live, and it is worth talking about with your doctor or a counsellor.
"A small rise on one report means it is turning into myeloma."
Results move a little between tests and laboratories. A steady rise across several tests, or a change in other blood results, is what matters.
"Treating MGUS early would stop myeloma."
No treatment has been shown to prevent change in MGUS. Careful follow-up allows early action if change does happen.
Being straight with you
What can this page not tell you?
This page cannot give you your personal risk. The risk groups above are a guide, and your haematologist also weighs your age, kidney function, other health problems and how your results have moved over time.
What lowers the stakes, whatever your group
Keeping follow-up appointments means a change is usually found while it is still small and before it harms your bones or kidneys. Reporting new symptoms early does the same. Neither needs you to worry every day.
What to ask at your next visit
Ask which risk group you are in and why. Ask what result would make your doctor want to see you sooner. Ask for a copy of each report, so the trend is kept together in one file.
Who closer checks do not suit
Extra scans and marrow tests are not helpful for everyone. For a person in the low-risk group, frequent testing adds cost, travel and worry without changing what happens. For a person who is very frail or has serious other illnesses, your doctor may agree a lighter plan that only tests when symptoms appear. Both are sensible choices, not neglect.
Reference ranges differ between laboratories. A single result is always read alongside symptoms and repeat tests.
Did you know
Myeloma almost always starts from MGUS, but the reverse is not true. Most people with MGUS never develop myeloma. Having one is not a sign that the other is on its way. MGUS is simply the stage at which a change, if it ever comes, can be spotted early.
Questions we are asked
Common questions about MGUS risk
What are my chances of getting myeloma?
The average is about 1 in 100 each year, but your own chance depends on your protein amount, type and light chain ratio. People in the low-risk group sit well below the average. Ask your haematologist which group you are in, because that is the figure that applies to you.
Can I do anything to lower my risk?
No diet, supplement or medicine has been shown to stop MGUS from changing. What you can control is follow-up. Keep your test dates, report new symptoms, look after your kidneys by drinking enough water, and check with your doctor before taking regular pain medicines.
Does my age change the risk?
MGUS is more common in older people, but the yearly chance of change is broadly similar across ages. A younger person simply has more years ahead in which change could happen, so follow-up tends to be kept up over a longer time.
My protein level went up slightly. Should I panic?
No. Small changes are common and can come from differences between laboratories or tests. Your doctor will look at the trend over several results and check your blood counts, calcium and kidney tests. A repeat test is usually the first step, not treatment.
Is IgM MGUS more dangerous?
IgM MGUS carries a somewhat higher chance of change, but it is watched mainly for a slow-growing lymphoma rather than myeloma. Your doctor may check your lymph glands, spleen and nerves as well as your blood. It still usually needs follow-up, not treatment.
If my MGUS changes, will I know?
Often the first sign is on a blood test before any symptoms. That is why follow-up matters. Between tests, tell your doctor about new bone pain, unusual tiredness, repeated infections, weight loss, frothy urine or numbness in the feet.
Should my brothers and sisters be tested?
Close relatives have a slightly higher chance of having MGUS, but routine testing of relatives without symptoms is not usually recommended. If a family member has symptoms or other abnormal blood results, their own doctor can decide whether protein tests are needed.
Can a low-risk group change to a higher one?
Yes. Your group is based on your latest results, so it can move if your protein amount or light chain ratio changes. That is one reason the first year of follow-up is often closer, and why each new report is compared with the earlier ones.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — What Is Multiple Myeloma?
- National Cancer Institute — Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ), Patient Version
- Blood Cancer UK — Myeloma
- Leukemia & Lymphoma Society — Myeloma
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Talk to us
Not sure which risk group you are in?
Share your protein test reports with us. Our haematology team will explain where your results place you and what follow-up makes sense.